Preferred Label : ponatinib;

MeSH note : a pan-Bcr-Abl protein kinase Inhibitor; structure in first source;

CISMeF synonym : AP24534;

MeSH synonym : 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;

MeSH hyponym : AP-24534; AP 24534;

MeSH Related Number : 96R6PU3D8J;

Is substance : O;

UNII : 4340891KFS;

InChIKey : PHXJVRSECIGDHY-UHFFFAOYSA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/portail/jcms/c_2780980/fr/iclusig
2017
false
false
false
France
French
evaluation of the transparency committee
administration, oral
ponatinib hydrochloride
ponatinib
ponatinib
imidazoles
pyridazines

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles

---
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
fusion proteins, bcr-abl
protein kinase inhibitors
Imatinib Mesylate
risk
hepatitis b virus
imatinib
nilotinib
nilotinib
bosutinib
bosutinib
Dasatinib
dasatinib
ponatinib hydrochloride
ponatinib
Tyrosine Kinase Inhibitor
Hepatitis B reactivation
guidelines for drug use
continuity of patient care
mass screening
hepatitis B
hepatitis B
Tyrosine Kinase Inhibitors
nilotinib
ponatinib
pyrimidines
imidazoles
pyridazines
aniline compounds
nitriles
quinolines

---
http://www.has-sante.fr/portail/jcms/c_2623462/fr/iclusig
2016
false
true
false
France
French
evaluation of the transparency committee
ponatinib hydrochloride
ponatinib
administration, oral
treatment outcome
antineoplastic agents
leukemia, myeloid, accelerated phase
blast crisis
leukemia, myeloid, chronic-phase
leukemia, lymphocytic, acute, L2
protein kinase inhibitors
orphan drug production
insurance, health, reimbursement
protein-tyrosine kinases
Tyrosine Kinase Inhibitors
precursor cell lymphoblastic Leukemia-Lymphoma
ponatinib
imidazoles
pyridazines

---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64793382
2013
summary of product characteristics
ponatinib
tablets
ponatinib
ponatinib hydrochloride

---
https://www.ema.europa.eu/medicines/human/EPAR/Iclusig
2013
false
United Kingdom
English
French
ponatinib
ponatinib
ponatinib
drug approval
europe
treatment outcome
drug evaluation
summary of product characteristics
package leaflet
syndication feed
orphan drug production
leukemia, lymphoid
leukemia, myeloid
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
imidazoles
imidazoles
pyridazines
pyridazines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63898099
2013
summary of product characteristics
tablets
ponatinib
ponatinib hydrochloride
ponatinib

---
Nous contacter.
14/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.